Pathway Bioventures — Full Portfolio
18 tracked investments · listed companies and verified rows first
Cytovale develops microfluidic deformability cytometry technology for immune response diagnostics, with a focus on early detection and diagnosis in hospital settings.
BiotechDigital HealthHealthtechMedical DevicesSan Francisco, US
Ajay Shah(Co-founder & CEO)inHenry Tse(Co-founder & Chief Technology Officer)inDino DiCarlo(Director, Promoter)
BoardLindy Fishburne(Director)inJack Fuchs(Director, Promoter)in
Co-investorsAlumni VenturesBasecamp FundBlackhorn VenturesBreakout LabsBreakout VenturesEMV Capital+3 more
Specialist investor in advanced modalities including cell, gene, RNA, and targeted therapies
4BIO Capital is an investment firm focused on early-stage advanced therapies targeting chronic disease.
BiotechDeep TechLondon, GB
Afference develops neurotechnology that enables remote sensory perception through wearable devices, allowing people at a distance to share tactile sensations.
AI & Machine LearningDeep TechHardwareHealthtechCleveland, US
Jacob Segil(Co-founder & CEO)inDustin Tyler(Co-founder & CTO)in
BoardTaylor Hurst(Director)inTrevor Zimmerman(Director)in
Co-investorsAnthropy PartnersCWRU Technology VenturesEvolution VC PartnersHannah Grey VenturesJobsOhio VenturesKonvoy Ventures+6 more
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane V. Hegarty(Chief Scientific Officer & Co-Founder)inJoanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)inTiasha Shafiq(Chief of Staff)in
BoardCorey . Goodman(Director)inJonathan Leff(Director)in
Co-investorsvenBio PartnersMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture Partners+7 more
Developing bispecific antibodies for precision autoimmune applications
Co-investorsPfizer Venture Investments
Preclinical-stage company developing next-generation gamma delta T cell engagers for solid and haematological malignancies.
Co-investorsSound Bioventures
Cytospire Therapeutics develops multispecific antibodies and next-generation γδ T cell engagers designed to direct innate and adaptive immune effector cells as an alternative to CD3-based engagers.
BiotechHealthtech
Co-investorsCriteria Bio VenturesLifeArc VenturesMedical Incubator Japan K.K.Modi VenturesSound Bioventures
Dimension Bio is a biotechnology company that designs and manufactures regenerative therapeutics using its BioNidum™ platform to restore tissue function lost to disease, trauma, or aging.
BiotechHealthtechNew MaterialsChicago, US
Caralynn Nowinski Collens, M.D.(Co-founder & CEO)inRamille Shah, Ph.D.(Co-founder & CSO)Ramille Shah(Director)Caralynn Collens(Executive Officer, Director)inAdam Jakus(Executive Officer, Director)in
BoardRima Chakrabarti(Director)in
Co-investorsBetter Ventures Central LlcLofty VenturesPortal InnovationsSolas BioVenturesKdT Ventures
IpiNovyx Bio is a biotech company developing potent and selective immunoproteasome inhibitors to treat cancer, autoimmune, and inflammatory diseases.
BiotechHealthtechMedical DevicesWest Nyack, US
Gang Lin(Scientific Founder)Carl Nathan(Scientific Founder)Franck Barrat(Scientific Founder)inMarc Appel(Executive Officer, Director)Lutz Giebel(Director)James Graham(Director)
Co-investorsAlexandria
miRecule is a biotechnology company developing therapeutics, with programs focused on oncology.
BiotechHealthtechGaithersburg, US
Anthony D. Saleh(CEO)inDave Lemus(COO/CFO)inAnthony D. Saleh, Ph.D.(CEO)in
Co-investorsBrown and White VenturesTachyon VenturesAlexandria
MODIFI provides a digital platform for cross-border trade finance, letting exporters and importers onboard online, receive payment right after shipping, and track trades and supplier payouts in one dashboard.
FintechLogistics & Supply ChainSaaSBainbridge Island, US
Jan Wehrs(Founder)inSven Brauer(Founder)inNelson Holzner(Co-Founder & CEO)inJames Poss(Executive Officer, Director, Promoter)Matthew Otepka(Executive Officer)J. Todd Larson(Executive Officer)
Co-investorsIncubate FundMaersk GrowthNeva Sgr.PICUS CAPITALGlobal Founders CapitalHighCape Capital
Modifi Bio presents itself as a research-focused biopharmaceutical company developing medicines and vaccines.
BiotechHealthtechNew Haven, US
Ranjit Bindra(Director)Kingson Lin(Cofounder)inKevin L. Rakin(Executive Officer, Director)
BoardLucas de Breed(Director)Kat Kayser-Bricker(Director)
Co-investorsConnecticut InnovationsHighCape CapitalIronwood Capital
Nionyx develops gene therapies, focusing on the design of viral capsids, expression cassettes, and delivery systems for precision and safety.
BiotechDeep TechHealthtech
Co-investors2048 VenturesACADEMY INVESTORAIN Ventures
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(Founder/CSO)inJack O'Meara(Founding CEO)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaHoxton Ventures+6 more
Scioto Biosciences is a life sciences company with corporate offices and research facilities in Fishers, Indiana.
BiotechDeep TechDigital HealthIndianopolis, US
Joe Trebley(Founder & Chief Executive Officer)inJim Schulz(Founder & Chief Financial Officer)inMark Heiman(Chief Science Officer)inKevin Meyer(Chief Operating Officer)in
Co-investorsElevate VenturesIU VenturesMichigan Capital Network
Simergent develops medical device systems for regulated healthcare markets, with expertise in peritoneal dialysis and infusion pump technologies.
BiotechHealthtechMedical DevicesChicago, US
Steve J. Lindo(Co-founder & CEO)inRick Pendergraft(Co-founder & Chief Technology Officer)inDr. James Sloand(Chief Medical Officer)Michael Rohleder(Manager)
Co-investorsAngel Physicians FundPlains Ventures
AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.
AI & Machine LearningBiotechDeep TechHealthtechStanford, US
Thorsten Stafforst(Chairman of the Board of Directors)inKris ElveruminTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in
BoardRodger Novak(Chair)
Co-investors+ND CapitalARCH Venture PartnersForbionVenrockFast Track InitiativeNextech Invest+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.